News | April 30, 2021
Indian vaccine players to garner Rs. 70,599 Cr in 2021
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Subscribe To Our Newsletter & Stay Updated
